3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
5
Medulloblastoma
4
Recurrence
3
Basal Cell Nevus Syndrome
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hepatoblastoma
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Blood Platelet Disorders
1
Blood Coagulation Disorders
1
Interventions
Azacitidine
14
venetoclax
10
AP 1903 reagent
7
Rituximab
6
Dexamethasone
6
Itraconazole
5
Cytarabine
5
Bortezomib
5
fludarabine
4
fedratinib
4
belinostat
4
Nivolumab
4
Lenalidomide
4
Imatinib Mesylate
4
Daunorubicin
4
ARQ531
4
pomalidomide
3
ibrutinib
3
daratumumab
3
cc-486
3
angiotensin I (1-7)
3
Standard of Care
3
GSK2110183
3
Cyclophosphamide
3
zanubrutinib
2
tosedostat
2
tazemetostat
2
tanespimycin
2
talquetamab
2
tafasitamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts